Benzodiazepines, anxiolytics and hypnotics

• Benzodiazepines are GABA-A receptor enhancers used for short-term control of severe anxiety, panic, insomnia, seizures, alcohol withdrawal and procedural sedation. They work within minutes to hours but carry a well-established risk of tolerance, dependence and withdrawal.
• The class is divided by duration of action. Long-acting agents such as diazepam and clonazepam have active metabolites and half-lives that can exceed a day; short-acting agents such as alprazolam, lorazepam and temazepam are cleared in hours and are more likely to cause inter-dose withdrawal and rebound insomnia.
• Benzodiazepines are not first-line treatment for generalised anxiety disorder or panic disorder. Current guidance (NICE CG113) reserves them for short-term crisis use in generalised anxiety and advises against prescribing them for panic disorder; SSRIs, SNRIs and cognitive behavioural therapy come first. ^[2]
• Dependence is an expected effect, not a moral failing. Prescribing should start low, be shared, include a plan to stop, and be reviewed regularly (NICE NG215, MHRA 2026). Stopping abruptly risks severe withdrawal, including seizures, so taper slowly over weeks or months.
• Z-drugs, buspirone and beta-blockers are the common alternatives. Z-drugs act at the same receptor subset and share most of the same risks; buspirone is slower but non-sedating and not dependence-forming; beta-blockers such as propranolol suppress the physical symptoms of anxiety without treating the fear itself.

By the end of this page you should be able to:

1. Explain how benzodiazepines act on the GABA-A receptor and why that produces anxiolysis, sedation, muscle relaxation, anticonvulsant effects and amnesia.
2. Group the named benzodiazepines by potency and by duration of action, and give the approximate dose equivalents relative to diazepam.
3. State the evidence-based indications and the situations in which benzodiazepines should be avoided or used only briefly.
4. Distinguish tolerance, therapeutic-dose dependence and misuse, and outline a slow, person-centred taper.
5. Compare benzodiazepines with Z-drugs, buspirone, beta-blockers and the SSRIs/SNRIs used first line for anxiety.
6. Apply safe-prescribing principles (NICE NG215, MHRA 2026) and recognise the drug interactions that matter most.

Benzodiazepines are a family of drugs that enhance the action of gamma-aminobutyric acid (GABA), the brain's main inhibitory neurotransmitter. Their clinical use began in the 1950s (chlordiazepoxide was synthesised in 1955) and they largely replaced barbiturates, because they have a wider safety margin and are rarely fatal in overdose on their own. ^[5] They remain among the most widely prescribed psychotropic medicines worldwide, with surveys reporting that 5 to 10 percent of adults in high-income countries receive at least one benzodiazepine prescription in a year. ^[5]

The clinical portrait is a paradox that runs through the whole topic. In the first days of use, a benzodiazepine can be genuinely valuable: it can stop a panic attack, rescue a sleepless night, abort status epilepticus or smooth alcohol withdrawal. With continued use, the same mechanism that produces relief begins to erode it, through tolerance to anxiolytic and hypnotic effects, and the nervous system adapts so that stopping becomes difficult and potentially dangerous. Nearly all the serious harms come from long-term or high-dose use, which is why the single most important message is that benzodiazepines are for short-term use only, generally no more than 2 to 4 weeks. ^[4][5]

This page covers the mechanism shared by the whole class, the individual agents and how long they act, their indications and dosing, adverse effects and why each happens, contraindications, interactions, monitoring, overdose, special situations such as pregnancy and hepatic impairment, and the related drugs: Z-drugs, buspirone and beta-blockers. Safe prescribing and withdrawal are treated as central, not as an afterthought.

By convention, and by marketing, benzodiazepines are grouped by their main clinical aim, but the underlying pharmacology is the same for all of them.

• Anxiolytics (tranquillisers): diazepam, chlordiazepoxide, lorazepam, alprazolam, oxazepam, bromazepam, clonazepam (also an anticonvulsant).
• Hypnotics (sleeping tablets): nitrazepam, temazepam, loprazolam, lormetazepam, flurazepam, flunitrazepam.
• Anticonvulsants/emergency drugs: midazolam (buccal or intranasal for prolonged seizures), diazepam (rectal or intravenous), lorazepam (intravenous), clonazepam.
• Procedural sedatives: midazolam (short-acting, intravenous), often used for endoscopy and minor surgery.

Potency and duration of action are combined in the classification from Samardzic et al. 2026. ^[5]

Two consequences follow from this table. First, a long half-life is not automatically better: diazepam and clonazepam smooth out inter-dose withdrawal, but drug accumulation is a real risk, above all in older adults and in hepatic impairment. Second, a very short half-life carries its own penalty for daily anxiety use, because plasma levels fall before the next dose, producing withdrawal symptoms between doses and a craving for the next tablet. ^[4][5]

Equivalent doses vary widely; potency differences can be 20-fold. ^[4] The approximate oral dose equivalents given as diazepam 10 mg are listed below, from Samardzic et al. 2026 (these are estimates and should be individualised). ^[5]

These figures are a guide for conversion, for example when substituting a long-acting benzodiazepine such as diazepam during a taper. ^[5] They are not interchangeable without clinical monitoring.

All benzodiazepines are positive allosteric modulators of the gamma-aminobutyric acid type A (GABA-A) receptor, the main inhibitory receptor in the central nervous system. ^[5] The receptor is a pentameric chloride channel, most often with two alpha, two beta and one gamma subunit. GABA itself binds between an alpha and a beta subunit and opens the chloride channel: chloride enters the neuron, hyperpolarises it and raises the threshold for firing. The benzodiazepine binding site sits between an alpha and the gamma subunit. When a benzodiazepine occupies it, the receptor's affinity for GABA increases, so the channel opens more often. The drug does not open the channel by itself: it only potentiates GABA. That is the reason benzodiazepines are safer in overdose than barbiturates, which can directly gate the channel. ^[5]

The clinical effects are mapped to alpha-subunit combinations: activation of alpha-1 subunits is linked to sedation, hypnosis and amnesia; activation of alpha-2 and alpha-3 to anxiolysis and muscle relaxation; and alpha-5 to cognitive impairment. ^[5] In practice this explains why different agents, despite sharing one mechanism, feel different: a drug with more prominent alpha-1 activity is a better sleeping tablet, one with stronger alpha-2 effects is a better anxiolytic. Because enhanced inhibition of GABA also reduces the output of excitatory neurotransmitters such as noradrenaline, serotonin, acetylcholine and dopamine, benzodiazepines touch almost every brain function, from attention and memory to muscle tone, endocrine secretion and autonomic control. ^[4]

The Ashton manual summarises the five therapeutic actions that all benzodiazepines share: anxiolytic, hypnotic, myorelaxant, anticonvulsant and amnesic. ^[4] These are the basis of every indication below.

Absorption after oral dosing is good and rapid; many agents can also be given intravenously in emergencies. Benzodiazepines are highly lipophilic, are extensively protein-bound, and distribute into adipose tissue, where they accumulate with repeated dosing. ^[5] Metabolism is hepatic, by two routes: glucuronide conjugation, or oxidation/demethylation followed by conjugation. Oxazepam and lorazepam already carry a hydroxyl group and undergo direct conjugation without oxidative metabolism, so they have shorter half-lives and less accumulation potential. Most others are oxidised first, often producing active metabolites such as desmethyldiazepam, which prolongs elimination and increases accumulation risk, particularly with long-term use. ^[5]

Representative pharmacokinetic figures from Samardzic et al. 2026 give a time to peak of 1 to 2 hours (product labelling gives an average of 1 to 1.5 hours, range 0.25 to 2.5 hours, and Wikipedia gives 30 to 90 minutes), plasma protein binding of 98 percent (96 to 99 percent in other references) and an average elimination half-life of 20 to 100 hours for diazepam; 1 to 6 hours, 85 to 91 percent and 10 to 20 hours for lorazepam; 1 to 4 hours, 84 percent and 20 to 60 hours for clonazepam; 1 to 2 hours, 80 percent and 6 to 27 hours for alprazolam; and 1 hour, 95 percent and 1.5 to 2.5 hours for midazolam. ^[5][8] In older adults and in hepatic impairment both clearance falls and the central nervous system becomes more sensitive, so the same dose has a larger and longer effect. ^{[5][7] [4]}

Modern indications described in the review literature and guidelines include the following. ^[2][5]

• Psychiatry: brief treatment of severe acute anxiety and panic; crisis and adjunctive use during the first weeks of SSRI or SNRI treatment in generalised anxiety; severe agitation or mania as an adjunct to antipsychotic treatment; severe insomnia, when first-line measures have failed.
• Neurology: status epilepticus (first-line drug treatment) and prolonged seizures; some forms of epilepsy as planned adjunctive therapy.
• Acute medicine and anaesthesia: alcohol withdrawal, particularly severe or delirium tremens; premedication and procedural sedation; acute dystonia.
• General medicine: muscle spasm and spasticity; selected stress-related or pre-procedural anxiety in people who understand the risks.

Benzodiazepines should not be used as the sole treatment of depression or of anxiety associated with depression, because of the risk of worsening the mood disorder. ^[4] NICE CG113 (last reviewed 11 September 2026) is explicit for generalised anxiety disorder: do not offer a benzodiazepine except as a short-term measure during crises. ^[2] For panic disorder, benzodiazepines are associated with a worse long-term outcome and should not be prescribed for its treatment; the same guideline reserves antidepressants for longer-term pharmacological treatment and cognitive behavioural therapy for psychological treatment. ^[2] In practice, this means benzodiazepines are a bridge, not a destination.

Doses should always be the lowest effective dose, started at the bottom of the range and titrated slowly, following the product information and local formulary. ^[1][5][8]

• Diazepam (from its product information): anxiety, 2 to 10 mg two to four times daily; acute alcohol withdrawal, 10 mg three or four times during the first 24 hours reducing to 5 mg three or four times daily; adjunct for muscle spasm or convulsive disorders, 2 to 10 mg two to four times daily; geriatric or debilitated patients, 2 to 2.5 mg once or twice daily initially, increased gradually; paediatric patients (not under 6 months), 1 to 2.5 mg three or four times daily initially, increased gradually. ^[8]
• Short-acting and high-potency agents (lorazepam, alprazolam, oxazepam, temazepam, clonazepam): titrate from small initial doses according to their own labels and the local formulary; approximate dose equivalents to diazepam are given in the table above and are used when converting for a taper. ^[4][5]
• Clonazepam is usually reserved for epilepsy, panic or situations needing a long-acting high-potency agent; oxazepam is preferred in older adults because it has a short half-life without active metabolites. ^[4][5]
• Lorazepam is often chosen when hepatic impairment is a concern, because it does not produce long-acting active metabolites. ^[4]

Children and adolescents require lower initial doses with slow titration, and most benzodiazepines are not licensed in children; emergency use for seizures follows separate protocols. Older adults should receive about half the usual adult dose. ^[4][1]

Because benzodiazepines potentiate inhibition, their adverse effects are, in a sense, the therapeutic effects taken too far or for too long.

• Oversedation, hangover and dizziness are dose-related. With long-acting agents the drug is still present the next day. Tolerance to sedation usually develops in a week or two, but fine judgement and some memory functions stay impaired. ^[4]
• Memory impairment is an extension of the amnesic therapeutic action. New learning is affected, especially episodic memory (recent events and their sequence), because attention and concentration suffer. Large single doses produce the anterograde amnesia used peri-operatively. ^[4]
• Cognitive impairment and "pseudodementia" can develop with chronic use, particularly with long-acting drugs and in older adults, and can mimic a dementia. It is often reversible, or partly reversible, after withdrawal. ^[5]
• Paradoxical excitement: increased anxiety, irritability, insomnia, nightmares, disinhibition, aggression and even violent behaviour, most often in anxious or aggressive individuals, children and older adults. ^[4]
• Depression and emotional blunting: chronic benzodiazepine use can both cause and aggravate depression, probably through reduced output of serotonin and noradrenaline, and can produce a flattening of emotion that patients themselves later regret. ^[4]
• Falls and fractures are a serious risk in older adults, via sedation, ataxia and muscle weakness. Benzodiazepine use is associated with roughly a 1.5 to 2 fold increase in fall and fracture risk in older adults compared with non-users. ^[5]
• Road traffic and occupational accidents: reaction time, coordination and judgement are impaired, in a way comparable to moderate alcohol intoxication. ^[5]
• Tolerance: develops quickly to hypnotic effects (within weeks) and more slowly to anxiolytic effects. Tolerance to memory and cognitive effects is not complete. ^[4]
• Dependence: psychological and physical, can develop within weeks or months of regular use, at therapeutic as well as high doses. With long-term use 50 to 100 percent of patients have difficulty stopping because of withdrawal symptoms. ^[4] Around 35.8 percent of patients continue benzodiazepine therapy beyond 3 months and about 3 percent of the general population use benzodiazepines long term. ^[5]
• Abuse potential: high-dose recreational misuse is a minority but growing problem, and benzodiazepines are implicated in a significant proportion of fatal opioid overdoses through additive respiratory depression. ^[4][5]

Two separate phenomena are often confused, and distinguishing them matters for prescribing. ^[4]

• Tolerance is a reduced response to the same dose, so that more drug is needed for the same effect. It is partly due to down-regulation and subunit changes in GABA-A receptors and to restoration of excitatory tone in downstream systems.
• Dependence is a state in which the body has adapted to the drug and produces symptoms when it is removed. Physical dependence can develop within weeks or months of regular use at therapeutic doses.
• Therapeutic-dose dependence describes people who take prescribed, usually low doses for months or years, gradually feel that they need the drug for normal function, find it hard to stop because of withdrawal symptoms, become anxious between doses (especially with short-acting agents) and continue to take the drug after the original indication has resolved. ^[4]
• Prescribed high-dose dependence and recreational misuse are less common but are associated with more severe withdrawal, including seizures, and with polydrug use. ^[4]

UK guidance classifies tolerance as a marker of dependence: a patient who reports that the medicine is less effective, or that a higher dose is needed, may be developing tolerance. ^[3]

Absolute or strong contraindications include hypersensitivity; acute respiratory failure or respiratory depression; severe sleep apnoea; myasthenia gravis; acute angle-closure glaucoma; porphyria; severe hepatic impairment (with some agents); pregnancy (relative, see below). ^[5][4]

Cautions and situations requiring specialist advice: chronic obstructive pulmonary disease (prescribe with extreme caution under close monitoring); obesity (increased volume of distribution and accumulation); major depressive disorder, bipolar disorder and psychotic disorders (risk of worsening symptoms and of impulsivity); cognitive impairment and dementia; a history of substance misuse; older adults (Beers Criteria recommend that benzodiazepines generally be avoided in older adults). ^[5][2]

• Central nervous system depressants (alcohol, opioids, gabapentinoids, sedating antihistamines, other hypnotics, antipsychotics, tricyclics, anticonvulsants) produce additive sedation, cognitive impairment and respiratory depression. Benzodiazepine-opioid co-prescription has been strongly associated with increased overdose mortality and should be avoided where possible. ^[5]
• Respiratory risk: gabapentinoid co-prescription (gabapentin, pregabalin) adds respiratory depression, particularly in older adults and in chronic lung disease. ^[1][5]
• Triazolam/flurazepam note: co-administration with buspirone did not prolong or intensify their sedative effects. ^[6]
• Enzyme-mediated: drugs that inhibit CYP3A4 increase benzodiazepine or buspirone levels; inducers reduce them. Tobacco smoke induces CYP1A2 and alters related drug levels. ^[6]
• Alcohol: grapefruit and some antifungals are relevant for buspirone (CYP3A4) but not the typical benzodiazepines metabolised by oxidation. ^[6]

Monitoring should follow NICE NG215: regular reviews, by phone, video or face to face, with frequency based on the person's circumstances, the drug and dose, and risk factors; extra unscheduled reviews if adverse effects occur, pregnancy is planned, health changes, or the person asks for a dose change. ^[1] Content of each review covers benefits and harms of continuing, adjusting or stopping, signs of dependence such as running out early, frequent requests for dose increases, or loss of effect, and the person's preferences. ^[1]

For cognitive outcome, regular checks for sedation, confusion, falls and (in at-risk groups) cognitive testing; in older adults, functional mobility and bone health. Prescribers should use standard risk tools for falls where available and report problems via the Yellow Card scheme. ^[3]

Benzodiazepine overdose exaggerates sedation and can depress respiration, especially when combined with alcohol or opioids. There is no routine antidote: treatment is supportive, with airway protection, fluid resuscitation, ECG monitoring and correction of electrolytes. ^[5] In confirmed overdose in a setting with airway expertise, flumazenil may be used under senior or anaesthetic direction; it can precipitate withdrawal in benzodiazepine-dependent patients and its effect can wear off before the benzodiazepine, so re-sedation must be watched for. ^[5] It should not be given if the person has seized. ^[5]

Benzodiazepines cross the placenta. Regular third-trimester use, even at therapeutic doses, can produce the "floppy infant" syndrome (hypotonia, oversedation, poor feeding) and withdrawal symptoms after birth, with onset ranging from a few days to about 3 weeks depending on the agent used, and with hyperexcitability, high-pitched crying and feeding difficulty. ^[4] There is little evidence of major congenital malformation with therapeutic doses, but chronic maternal use may impair fetal growth and brain development, with concern about later attention and learning problems. ^[4] The product information advises that use in pregnancy should be avoided where possible, that sedation in the neonate is a risk, and that if treatment is necessary the lowest dose should be used for the shortest time. ^[4]

During breastfeeding, benzodiazepines pass into breast milk in small amounts; if used, use the lowest dose and monitor the infant for sedation, feeding and breathing. ^[4]

• Renal: most benzodiazepines are hepatically metabolised, so dose changes are not always needed, but accumulation of active metabolites is a risk in older and sicker patients.
• Hepatic: oxidation is slowed in liver disease. Agents that use direct conjugation (lorazepam, oxazepam, temazepam) are generally better tolerated than those with active metabolites (diazepam, chlordiazepoxide). In severe liver impairment, avoid benzodiazepines or use a reduced dose with close monitoring. ^[4][2]
• Older adults: metabolise the drugs less efficiently and are more sensitive at the same plasma concentration; dose about half the adult dose and prefer short-acting agents without active metabolites. ^[4]

Withdrawal features (acute) typically begin within hours to days after the last dose and can include rebound anxiety and insomnia, muscle pain and twitching, sensory hypersensitivity, depersonalisation and derealisation, dizziness, tremor, autonomic overactivity, perceptual disturbances and, at worst, seizures. ^[4] Symptoms may appear at any time during withdrawal, be delayed, change over time or persist; it is often hard to distinguish withdrawal from relapse of the underlying condition. ^[1]

Principles of dose reduction from NICE NG215: ^[1]

• Do not stop abruptly unless there are exceptional medical circumstances (for example respiratory depression or severe ataxia); otherwise taper gradually.
• Agree a slow, stepwise rate of reduction proportionate to the dose, so that decrements become smaller as the dose is lowered. A rate of about 5 to 10 percent of the total daily dose every 2 to 4 weeks is commonly cited as a starting point, with slower reductions at lower doses and in long-term users. ^[5]
• For short-half-life benzodiazepines, consider switching to a long-acting agent such as diazepam before tapering. ^[1]
• Modify the schedule to allow intolerable symptoms to settle before the next step.
• Give the person additional control where practical (for example issuing doses that can be cut, so reductions happen at their pace).
• Consider group cognitive behavioural therapy to support withdrawal. ^[1]
• Do not treat withdrawal with another dependence-forming drug, and specifically do not use sodium valproate or buspirone to aid benzodiazepine withdrawal. ^[1]

Replacement doses for substitution are approximate: about 0.5 mg alprazolam, 1 mg lorazepam or 0.5 mg clonazepam is considered roughly equivalent to 10 mg diazepam. ^[5] After conversion, reduction proceeds over weeks to months depending on response. ^{[5] [4]}

Typical adult withdrawal (Ashton, chapter II) illustrates gradual reduction: from a daily dose of diazepam 40 mg (or its equivalent) the dosage may be reduced by 2 to 4 mg every one to two weeks until 20 mg daily, then by 1 to 2 mg every one to two weeks, with the last 5 mg often reduced by about 0.5 mg at a time. Where someone is on a high dose such as alprazolam 6 mg daily, this is converted to a diazepam-equivalent dose of about 120 mg before reduction begins. ^[4] Ashton's schedule is faster than the slow, stepwise reduction NICE NG215 advises (decrements proportionate to the dose, typically about 5 to 10 percent of the daily dose every 2 to 4 weeks), so local guidance and the person's response should set the pace; many people complete the last part of a taper with 1 mg or 0.5 mg diazepam. ^{[4] [1] [5]} Older adults can withdraw successfully with a similarly slow taper. ^[4]

Z-drugs are chemically distinct from benzodiazepines but act as positive allosteric modulators at the same GABA-A receptor, with relative selectivity for alpha-1 subunits, which explains their prominent hypnotic effects. ^[5] They are licensed for short-term insomnia. Because of the shared mechanism they share much of the same profile: sedation, cognitive impairment, falls and fractures in older adults, tolerance, dependence, withdrawal and rebound insomnia. ^[5] Z-drugs therefore cannot be treated as a safer alternative to benzodiazepine sleeping tablets, and current guidance limits them to short-term use with the same tapering approach. ^[3][5] Zopiclone is converted to diazepam in the substitution tables of the Ashton manual, reflecting this mechanistic overlap. ^[4]

Buspirone is an azapirone anxiolytic, chemically unrelated to benzodiazepines. It is an agonist at the serotonin 5-HT1A receptor with moderate affinity for central D2 receptors; it has no affinity for benzodiazepine receptors and does not modulate GABA binding. ^[6] Its advantages are that it is not sedating, does not impair psychomotor performance or enhance alcohol's effects, and does not produce tolerance, physical or psychological dependence, or a withdrawal syndrome. ^[6] Its disadvantages are that it is slower acting (anxiolytic effect builds over several weeks), is less effective for panic or severe acute anxiety, and is not a muscle relaxant or anticonvulsant. ^[6]

Indication from the label: management of anxiety disorders, or short-term relief of the symptoms of anxiety; daily anxiety not usually needing pharmacotherapy. Efficacy has been demonstrated in generalised anxiety disorder. ^[6]

Dosing from the label: initial dose 15 mg daily (7.5 mg twice daily); increase by 5 mg every 2 to 3 days as needed, to an optimum of 20 to 30 mg daily; maximum 60 mg daily. Take consistently with regard to food. ^[6] Buspirone is metabolised by CYP3A4, so strong inhibitors (erythromycin, itraconazole, nefazodone, ritonavir, ketoconazole, grapefruit juice, diltiazem, verapamil) require much lower doses or avoidance, and inducers (rifampin, carbamazepine, phenytoin, phenobarbital, dexamethasone) reduce its effect. ^[6] In severe hepatic or renal impairment it should not be used. ^[6] Buspirone has no cross-tolerance with benzodiazepines and will not block benzodiazepine withdrawal; people switching must be withdrawn gradually from the benzodiazepine first. ^[6] Note that NICE NG215 specifically advises against using buspirone to aid benzodiazepine withdrawal. ^[1]

Beta-blockers such as propranolol act peripherally and centrally on beta-adrenergic receptors and suppress the somatic symptoms of anxiety (tachycardia, tremor, sweating, dry mouth) by damping sympathetic overactivity, but they do not treat the subjective feeling of fear, worry or panic. ^[7] They are unsuitable as monotherapy for generalised anxiety disorder or panic disorder but are used for situational or performance anxiety (stage fright, test anxiety, dental phobia, examination tremor). ^[7]

Evidence reviewed by Zhao et al. 2026 shows that propranolol 160 mg daily markedly reduced the physical manifestations of anxiety (shortness of breath, chest pain, weakness) in chronic anxiety, with a meta-analysis suggesting comparable short-term efficacy to benzodiazepines for panic but lacking long-term evidence. ^[7] The same review emphasises that low-dose or intermittent strategies minimise fatigue and attention problems, that pre-existing cognitive impairment may worsen on prolonged use, and that depression is a complex, dose-dependent concern. ^[7] Cautions include asthma, chronic obstructive pulmonary disease, bradyarrhythmia and atrioventricular block, diabetes, psoriasis and depression.

NICE NG215 treats benzodiazepines, Z-drugs, opioids, gabapentinoids and antidepressants as medicines that can cause dependence or withdrawal, and builds prescribing around these habits. ^[1]

• Before starting: confirm that all suitable management options, including non-drug approaches and watchful waiting, have been discussed and offered. ^[1]
• Risk factors: a comorbid mental health diagnosis, past drug or alcohol misuse, lack of a clear diagnosis, and taking an opioid with a benzodiazepine. These raise risk but do not automatically bar prescribing; explain and discuss them. ^[1]
• Information: give verbal and written information before starting, covering side effects, pregnancy implications, options if the drug does not work, how hard it will be to stop, and that missing doses can trigger withdrawal. ^[1]
• Dependence is expected: dependence with these medicines is an expected effect, not a reason in itself to withhold them, but patients must know the potential for problems. ^[1]
• Management plan: agree and document the reason for prescribing, the intended outcomes, starting dose and titration intervals, duration of each prescription, who to contact, overdose advice, and the next review date. ^[1]
• Strategy: start at a low dose, agree frequent regular reviews, find the lowest effective dose, and do not automatically increase the dose if response is not sustained. Avoid routine combined antipsychotics or combined sedatives. ^[1]
• Prescription duration: should reflect the management plan and controlled-drugs legislation. ^[1]
• Review: regular reviews, increasing frequency during dose adjustment and providing unscheduled reviews when needed. ^[1]
• Deprescribing: do not stop abruptly unless exceptional circumstances; agree a slow stepwise reduction with smaller decrements at lower doses; for short-half-life benzodiazepines consider switching to a long-acting agent. ^[1]
• Patient resources: the MHRA (January 2026, Drug Safety Update volume 19, issue 6) has strengthened warnings on packaging and labels and produced patient leaflets on the risks of addiction, dependence and withdrawal for benzodiazepines, Z-drugs and gabapentinoids, recommending that they accompany prescribing. ^[3]
• Reporting: suspected adverse drug reactions, including dependence, withdrawal or tolerance, should be reported via the Yellow Card scheme. ^[3]

The MHRA also reminds prescribers that tapering from a high dose may take weeks or months and that patients should be told this from the start, should be advised never to stop without speaking to a professional first, and should be supported regularly if they have a history of substance use disorder or mental health disorder. ^[3]

• Older adults: avoid benzodiazepines where possible; if essential, use about half the adult dose, prefer short-acting agents without active metabolites, and treat for no more than 2 weeks. Report sedation, confusion, falls and "pseudodementia" early. ^[4][5]
• Pregnancy: avoid if possible; if needed, use the lowest dose for the shortest time, avoid the third trimester where feasible, and arrange specialist obstetric and psychiatric input. ^[4]
• Breastfeeding: small amounts pass into milk; if used, lowest dose and monitor the infant. ^[4]
• Hepatic impairment: prefer conjugated agents, avoid if severe. ^[4]
• Substance use history: cautious prescribing, with closer monitoring, because of misuse risk. ^[5]
• Children: not routine; emergency use for seizures follows separate protocols. ^[1]
• Low-resource settings: where cognitive, biochemistry or drug-level monitoring are unavailable, use the minimum effective dose, keep regimens simple, avoid polypharmacy, plan the duration and exit at the start, give written instructions that fit literacy, teach patients and carers the signs of dependence and withdrawal, and arrange earlier follow-up for high-risk groups.

• Thinking "atypical" in the antipsychotic sense applies here: all benzodiazepines depend on the same mechanism and share the same 2 to 4 week limit.
• Prescribing for chronic insomnia or chronic anxiety instead of CBT and cognitive behavioural therapy for insomnia; hypnotics are not a long-term solution. ^[5]
• Treating "anxiety" that is actually depression: benzodiazepines alone can worsen mood. ^[4]
• Using short-acting benzodiazepines for all-day anxiety: inter-dose withdrawal and craving follow. ^[4]
• Forgetting that diazepam's active metabolites make it long-acting and accumulative, especially in older adults and liver disease.
• Forgetting that high-dose long-term users need months of taper, with smaller decrements at lower doses.
• Confusing rebound insomnia with relapse and escalating the dose.
• Assuming Z-drugs are safe because they are "non-benzodiazepine": they share the same GABA-A mechanism and the same risks. ^[5]
• Forgetting that buspirone does not work immediately and does not cover panic or acute crisis. ^[6]
• Forgetting that propranolol treats the body, not the mind, in anxiety, and that it is contraindicated in asthma and significant bradyarrhythmia. ^[7]
• Stopping benzodiazepines suddenly in a dependent patient: risk of severe withdrawal including seizures. ^[1][4]

• Benzodiazepines enhance GABA-A receptor function by positive allosteric modulation; they do not open the chloride channel without GABA, which underlies their better overdose safety than barbiturates.
• Therapeutic actions are anxiolytic, hypnotic, myorelaxant, anticonvulsant and amnesic: this single profile explains all of their indications and most of their harms.
• Duration of action matters. Long-acting agents smooth inter-dose symptoms but accumulate; short-acting agents are cleared quickly and are more likely to produce rebound and inter-dose withdrawal.
• Potency varies up to 20-fold; approximate diazepam equivalents are alprazolam 0.5 mg, lorazepam 1 mg, clonazepam 0.5 mg and oxazepam or temazepam 20 mg for 10 mg diazepam. ^[4][5]
• Benzodiazepines are indicated for short-term crises, procedural sedation, seizures, alcohol withdrawal and severe insomnia after first-line measures have failed; they are not first-line for generalised anxiety disorder (except briefly in crises) and should not be prescribed for panic disorder.
• SSRIs and SNRIs, with cognitive behavioural therapy, are first-line for anxiety disorders; benzodiazepines are a short-term bridge. ^{[2] [5]}
• Dependence can develop within weeks to months at therapeutic doses; 50 to 100 percent of long-term users have difficulty stopping. ^[4]
• Taper slowly, typically 5 to 10 percent of the daily dose every 2 to 4 weeks with smaller steps at lower doses; switch short-acting agents to diazepam first; do not stop abruptly.
• Adverse effects include oversedation, anterograde amnesia, cognitive impairment, paradoxical excitement, depression, falls and fractures, traffic accidents and, with opioids, fatal respiratory depression.
• Z-drugs share the same GABA-A mechanism and the same 2 to 4 week limit and are not safer alternatives.
• Buspirone is non-sedating and non-dependence-forming but slower; do not use it to aid benzodiazepine withdrawal.
• Beta-blockers such as propranolol blunt somatic anxiety symptoms without treating the fear; they are contraindicated in asthma and significant bradyarrhythmia.
• Safe prescribing rests on clear indication, lowest effective dose, agreed management plan and stop date, regular review, patient information, and patient leaflets on dependence risks, per NICE NG215 and MHRA 2026.

Benzodiazepines are best learned alongside the anxiety disorders, sleep medicine, seizure management and alcohol withdrawal. Relevant MedGrasp topics include generalised anxiety disorder, panic disorder, insomnia, status epilepticus, alcohol use disorder, antipsychotic drugs and their adverse effects, opioid prescribing, and depression in adults.